GLP-1 drug market to hit $33.92b by 2034 as chronic diseases surge

Asia Pacific is expected to register the highest growth rate during the forecast period.

The GLP-1 market, an incretin hormone that plays a major role in glucose metabolism, is expected to reach $33.92b by 2034, according to a Polaris Market Research report.

According to the report, there is a growing use of this therapy in chronic disease management, such as diabetes and weight management.

Beyond type 2 diabetes, it is used to manage conditions such as obesity and cardiovascular risk. It also helps improve metabolic outcomes with fewer side effects and lower dosing.

In terms of type of GLP-1 agonist drugs, long-acting GLP-1 agonists led the market in 2025, driven by their extended dosing intervals and consistent clinical outcomes.

By administration, the oral GLP-1 segment is anticipated to grow fastest during the forecast period.

Asia Pacific is expected to register the highest growth rate during the forecast period, fueled by the surging prevalence of lifestyle-related metabolic disorders.